New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 26, 2012
12:22 EDTXLNX, CHK, XOM, BCO, ALU, PHM, EQIX, JNJ, NIHD, SWI, AKAM, REGN, CTXS, UPS, LEAP, PCS, AETOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday, in spite of jobless claims that were higher than expected and disappointing results from Exxon Mobil (XOM). Stocks began the day quietly following the jobless claims data. The averages were mixed in the opening half hour but spurted higher following the March pending home sales report. The data was much better than expected and pushed the averages to their session highs. The averages have since remained in a narrow range but have drifted higher... ECONOMIC EVENTS: Domestically, 388,000 initial jobless claims were reported, versus expectations of 375,000. Continuing claims came in at 3.31M, versus expectations for 3.29M. The Chicago Fed National Activity Index had a reading of -0.29. Pending home sales for the month of March were up 4.1% from the prior month, versus expectations of an increase of 1.0%... COMPANY NEWS: Exxon Mobil and UPS (UPS) both reported revenues and earnings that missed expectations, sending shares of both tumbling. Exxon slid almost 2% following its report, while UPS fell over 3%... Johnson & Johnson (JNJ) increased its dividend by 7%... Reuters reported that the SEC opened an informal inquiry into Chesapeake Energy's (CHK) well participation program as the company came out separately and said it did not review or approve of specific transactions made by its CEO Aubrey McClendon under that program... Among companies reporting earnings, advancers included Citrix Systems (CTXS), Equinix (EQIX), Xilinx (XLNX), Regeneron (REGN) and Pulte (PHM); decliners included Aetna (AET), Akamai (AKAM), Alcatel-Lucent (ALU) and MetroPCS (PCS)... MAJOR MOVERS: Among the notable gainers were SolarWinds (SWI), up 19%, after guiding to FY12 adjusted earnings that were above consensus at the midpoint, and Brinks (BCO), up over 17%, following results that beat on both the top and bottom line. Noteworthy losers included Leap Wireless (LEAP), down 20%, following downgrades at Raymond James and Guggenheim after its weak Q1 results, and NII Holdings (NIHD), down more than 18%, after its revenues and earnings disappointed... INDICES: Near noon, the Dow was up 63.46, or 0.48%, to 13,154.18; the Nasdaq was up 6.61, or 0.22%, to 3,036.24; and the S&P 500 was up 2.62, or 0.19%, to 1,393.31.
News For XOM;UPS;JNJ;CHK;CTXS;EQIX;XLNX;REGN;PHM;AET;AKAM;ALU;PCS;SWI;BCO;LEAP;NIHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
January 26, 2016
05:19 EDTCHKStocks with implied volatility movement; CHK FTR
Subscribe for More Information
January 25, 2016
16:00 EDTXOMOptions Update; January 25, 2016
Subscribe for More Information
16:00 EDTREGNRegeneron shares defended at BofA/Merrill
14:29 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
12:42 EDTJNJEarnings Watch: J&J shares little changed since last earnings report
Johnson & Johnson (JNJ) is scheduled to report fourth quarter earnings before the market opens on Tuesday, January 26, with a conference call scheduled for 8:30 am ET. Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. EXPECTATIONS: Analysts are looking for earnings per share of $1.42 on revenue of $17.88B, according to First Call. The consensus range for EPS is $1.39-$1.44 on revenue of $17.57B-$18.31B. LAST QUARTER: On October 13, Johnson & Johnson reported third quarter EPS of $1.49 on revenue of $17.1B. The company's Q3 EPS results exceeded average analyst expectations of $1.45 but its revenue came in less than analysts' expectations of $17.54B. With its Q3 results, the drug giant narrowed its EPS view for the year to $6.15-$6.20 from $6.10-$6.20, while maintaining its sales outlook of $75B-$76B. Worldwide Consumer sales of $3.3B for Q3 represented a decrease of 7.7% versus the prior year, consisting of an operational increase of 3.1% and a negative impact from currency of 10.8%. Worldwide Pharmaceutical sales of $7.7B for the third quarter represented a decrease of 7.4% versus the prior year with an operational decrease of 0.3% and a negative impact from currency of 7.1%. Domestic sales decreased 4.5%; international sales decreased 11.1%, which reflected an operational increase of 5.5% and a negative currency impact of 16.6%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.1%, domestic sales increased 11.5% and international sales increased 8.5%. Worldwide operational sales growth was driven by new products and the strength of core products. New product sales growth was negatively impacted by lower sales of Olysio/Sovriad due to competitive entrants. Strong growth in new products include Invokana/Invokamet, for the treatment of adults with type 2 diabetes; Imbruvica, an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; Xarelto, an oral anticoagulant; and Zytiga, an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. On January 19, Johnson & Johnson announced restructuring actions in its Medical Devices unit. The actions are expected to result in annualized pre-tax cost savings of $800M to $1B, the majority of which is expected to be realized by the end of 2018, including approximately $200M in 2016. With its restructuring announcement the company reiterated its prior adjusted EPS view of $6.15- $6.20. STREET RESEARCH: On December 18, Atlantic Equities analyst Steve Chesney initiated Johnson & Johnson with a Neutral rating and $95 price target. On December 1, Barclays analyst Geoff Meacham upgraded Johnson & Johnson to Overweight after assuming coverage of the name. J&J should post a strong year in 2017 and will likely boost its orphan diseases or oncology pipeline via capital deployment, Meacham tells investors in a research note. He raised his price target for shares to $115 from $101. PRICE ACTION Since reporting its Q3 results, Johnson & Johnson shares are up approximately 1%, and they are currently trading up fractionally in afternoon trading ahead of Tuesday's earnings report.
12:17 EDTJNJJohnson & Johnson technical notes before earnings
The key level for the shares heading into earnings is at the $90 to $88 area, which has been a zone of support since late 2013. If the news is bearish, shares could retest this area. A breakdown below $90 would confirm a long-term topping process is underway. If the news is bullish, the first important resistance level is at the $100 area. A breakout above $100 would put the 52-week high at $105.49 up as the next major upside objective.
10:55 EDTREGNRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:00 EDTREGNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
09:44 EDTCHKChesapeake downgraded to Sell from Hold at Tudor Pickering
Subscribe for More Information
09:08 EDTAETCalifornia seen asking for few remedies in health insurance mergers, CTFN says
Subscribe for More Information
09:03 EDTREGNOn The Fly: Pre-market Movers
HIGHER: Tyco (TYC) and Johnson Controls (JCI), up 9% and 1%, respectively, after announcing a definitive merger agreement. Johnson Controls shareholders will own approximately 56% of the equity of the combined company, while current Tyco shareholders will own approximately 44%... SunEdison (SUNE), up 10% after the Wall Street Journal reported that the company is set to give David Einhorn's Greenlight Capital a seat on its board... Affimed Therapeutics (AFMD), up 26% after entering a clinical research collaboration in immuno-oncology with Merck (MRK). UP AFTER EARNINGS: McDonald's (MCD), up 3%... LOWER: Twitter (TWTR), down 5% after its CEO Jack Dorsey confirmed in a tweet last night that several executives are departing the company. Media reports also indicate that, as part of its shake-up, Twitter intends to bring in two new members to its board as soon as this week... OncoMed (OMED), down 38% after an independent data safety monitoring board remarked on several findings regarding futility of the company's Phase 2 ALPINE clinical trial... Medivation (MDVN), down 7% after FDA places investigational new drug application for MDV9300 on partial clinical hold... International Paper (IP), down 4.8%, Packaging Corp. (PKG), down 4.8%, WestRock (WRK), down 6%, after Pulp & Paper Week reduced January kraftliner and corrugated medium prices... Caterpillar (CAT), down 4% after Goldman cuts rating to sell... Regeneron (REGN), down 3% after downgraded at Chardan to sell. DOWN AFTER EARNINGS: Kimberly-Clark (KMB), down 2.5%.
08:23 EDTAETLeerink sees 'strong' buying opportunity in Managed Care space
Subscribe for More Information
06:53 EDTJNJGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
06:04 EDTREGNRegeneron downgraded to Sell from Neutral at Chardan
January 24, 2016
11:02 EDTXLNXStocks post weekly gain after oil rebounds
Stocks recovered late in the week to post their first weekly gain of the new year as equities continue to be correlated closely with the oil market. A plunge in oil led equities lower early in the holiday shortened week, but as oil prices rebounded to close the week out, the major averages followed suit. MACRO NEWS: In the U.S., the consumer price index fell 0.1% during December, versus expectations for a flat reading. The core reading, which excludes food and energy, showed prices rose 0.1% from the prior month, versus expectations for an increase of 0.2%. Initial jobless claims rose to 293,000 last week, topping the expectation for 278,000 first-time claims. Markit's flash manufacturing Purchasing Managers' Index for January rose 1.5 points to 52.7, better than the 51.0 reading that was expected. Existing home sales climbed 14.7% to a 5.46M rate in December, topping the 5.2M rate that was forecast... In Asia, China's national bureau of statistics estimated that GDP growth slowed to 6.8% in the last quarter of the year, dipping from 6.9% growth in the previous quarter. China's industrial output rose 5.9% from a year earlier in December, compared with the consensus forecast for a 6% increase. Japan's Nikkei average was down early in the week, even falling into bear market territory, but rallied nearly 6% on Friday after the Nikkei Asian Review said that the Bank of Japan is taking a "serious look" at additional easing... In Europe, the European Central Bank left its key interest rates unchanged. However, at an associated press conference, ECB President Mario Draghi acknowledged downside risks were increasing again, meaning the bank may need to "review and possibly reconsider" its monetary policy stance at its next meeting in March. Markit's flash PMI for the euro zone slid to an 11-month low of 53.5, missing expectations for a more modest dip to a 54.2 reading. The International Monetary Fund cut its global growth forecasts for the third time in less than a year. The IMF now estimates that the world economy will grow 3.4% this year and 3.6% next year, down from its prior forecasts of 3.6% and 3.8% growth, respectively. COMPANY NEWS: On Tuesday, Morgan Stanley (MS) advanced 1% after its earnings and revenue topped analysts' consensus forecast. Big bank peer Bank of America (BAC) slid 1% after its earnings also beat expectations but its revenue narrowly missed the consensus estimate... On Wednesday, IBM (IBM) slid nearly 5% after reporting better than expected earnings and revenue for the fourth quarter, but forecasting below-consensus profits for the new year... On Thursday, Verizon (VZ) was among the best performers on the Dow, advancing over 3% after its earnings, revenue and wireless subscriber additions all topped expectations. Conversely, fellow Dow member Travelers (TRV) slid almost 1% after releasing its own quarterly results... On Friday, American Express (AXP) sunk more than 12% after the card issuer reported stronger than expected quarterly results but its 2017 profit guidance came in below the consensus outlook. The company's pledge to take out $1B in costs by the end of 2017 did little to change the mood of analysts or investors. Fellow Dow member GE (GE) slid a bit more than 1% after reporting better than expected earnings but lower than expected quarterly revenue... Schlumberger (SLB) shares gained 6% after the oil services giant reported earnings that topped expectations, approved a quarterly dividend of 50c per share and a new share repurchase program of $10B and said it plans to cut 10,000 more jobs... Netflix (NFLX) reported fourth quarter earnings that beat analyst estimates, powered by better than expected international subscriber growth. The numbers were met with positive commentary by several research firms, though decelerating U.S. subscriber growth was highlighted by bears as a warning sign for the company... Deutsche Bank (DB) disclosed that it expects a EUR2.1B net loss for the quarter due to a number of charges, including expected litigation costs of EUR1.2B... Xilinx (XLNX) advanced after reporting its third quarter numbers. The news may have been overshadowed, however, by a regulatory filing showing new agreements with its top executives, with several analysts highlighting that the change could signal a takeover is in the cards in the future... Alkermes (ALKS) plunged more than 44% after disclosing that two of three Phase 3 studies of its experimental depression disorder treatment did not meet their primary efficacy endpoints. INDEXES: For the four-day week, the Dow gained about 0.67% to close at 16,093.51, the S&P 500 rose about 1.4% to close at 1,906.90, and the Nasdaq increased about 2.3% to close at 4,591.18.
January 22, 2016
15:22 EDTJNJJohnson & Johnson volatility elevated into Q4 and outlook
Subscribe for More Information
11:33 EDTCTXSOptions with increasing call volume
Subscribe for More Information
09:28 EDTCHKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: 8x8, Inc. (EGHT), up 12.5%... Intuitive Surgical (ISRG), up 2.2%. ALSO HIGHER: Apple (AAPL), up 1.9% after Piper Jaffray's Gene Munster says that Apple could rally over 50% by September... Chesapeake Energy (CHK), up 6.4% after announcing that it is suspending its quarterly preferred stock dividends... NephroGenex (NRX), up 27.3% after the independent Data and Safety Monitoring Board recommendation to continue the Pyridorin study... Avon Products (AVP), up 4.4% after being upgraded to Overweight from Neutral at Piper Jaffray... Freeport-McMoRan (FCX), up 6.7% after Reuters reports that Indonesia asked the company to set aside another $530M into an escrow account for the miner to extend its permit to export copper concentrate. DOWN AFTER EARNINGS: American Express (AXP), down 6.9%... Starbucks (SBUX), down 2.6%... Cardiovascular Systems (CSII), down 32.3%... GE (GE), down marginally. ALSO LOWER: Barrick Gold (ABX), down 3.4% after giving fourth quarter and fiscal 2015 production guidance and announcing potential asset impairment charges of $1B-$1.2B.
08:59 EDTCHKChesapeake suspends quarterly preferred stock dividends
Subscribe for More Information
06:47 EDTXLNXXilinx deal possible, but not guaranteed, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use